Skip to main content
SpringerLink
Log in

Aromatase Inhibitors as New Endocrine Therapy for Breast Cancer

  • Chapter
Endocrine Therapies in Breast and Prostate Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 39))

Abstract

The role of estrogen in promoting the growth of hormone-dependent mammary tumors is well established. Inhibition of estrogen synthesis by selective blockade of the aromatase enzyme could be an effective systemic means of reducing estrogen production and treating patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Townsley J, Brodie HJ (1968): Studies on the mechanism of estrogen biosynthesis. III. The sterochemistry of aromatization of C19 and C18 steroids. Biochemistry 7:33–40.

    Article  PubMed  CAS  Google Scholar 

  2. Brodie HJ, Kripalani KJ, Possanza G (1969): Studies on the mechanisms of estrogen biosynthesis. VI. The stereochemistry of hydrogen elimination of C-2 during aromatization. J Am Chem Soc 91:1241–1242.

    Article  PubMed  Google Scholar 

  3. Morato T, Raab K, Brodie HJ, et al (1962): The mechanism of estrogen biosynthesis. J Am Chem Soc 84:3764–3767.

    Article  CAS  Google Scholar 

  4. Fishman J, Guzik H (1969): Stereochemistry of estrogen biosynthesis. J Am Chem Soc 91:2805–2806.

    Article  PubMed  CAS  Google Scholar 

  5. Worgul TJ, Santen RJ, Samojlik E, Wells SA (1982): How effective is surgical adrenalectomy in lowering steroid hormone concentrations? J Clin Endocrinol Metab 54:22–26.

    Article  PubMed  CAS  Google Scholar 

  6. Longcope C (1971): Metabolic clearance and blood production rates of estrogen in postmenopausal women. Am J Obstet Gynec 111:778.

    PubMed  CAS  Google Scholar 

  7. Hemsell DL, Grodin JM, Brenner PF, et al (1974): Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrogen with age. J Clin Endocrinol Metab 38:476.

    Article  PubMed  CAS  Google Scholar 

  8. Miller WR, Forrest APM (1974): Estradiol synthesis by a human breast carcinoma. Lancet 2:866.

    Article  PubMed  CAS  Google Scholar 

  9. Abdul-Hajj YJ, Iverson R, Kiang DT (1979): Aromatization of androgens by human breast cancer. Steroids 33:205.

    Article  Google Scholar 

  10. Valera RM, Dao TL (1978): Estrogen synthesis and estradiol binding by human mammary tumors. Cancer Res 38:2429.

    Google Scholar 

  11. Perel E, Wilkins D, Killinger DW (1980): The conversion of androstenedione to estrone, estradiol and testosterone in breast tissue. J Steroid Biochem 13:89.

    Article  PubMed  CAS  Google Scholar 

  12. Tseng L, Mazella J, Lee LY, Stone ML (1983): Estrogen sulfatase and estrogen sulfatransferase in human primary mammary carcinoma. J Steroid Biochem 19:1413.

    Article  PubMed  CAS  Google Scholar 

  13. Santner SJ, Feil PD, Santen RJ (1984): In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 52:29–33.

    Article  Google Scholar 

  14. Breast Cancer Consensus (1985): Science 229:1378.

    Article  Google Scholar 

  15. McGuire WL (1980): An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In Iacobell, S (ed): Hormones and Cancer, Vol 15. New York, Raven Press, pp 337–343.

    Google Scholar 

  16. Sherman BM, Chapler FK, Crickard K, Wycoff D (1979): Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64: 398–404.

    Article  PubMed  CAS  Google Scholar 

  17. Speroff L, Glass RH, Käse NG (1983): In Clinical Gynecology and Infertility, 3rd ed. Baltimore, Williams & Wilkins, pp 529–532.

    Google Scholar 

  18. Goss PE, Powles TJ, Dowsett M, et al (1986): Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res 46:4823–4826.

    PubMed  CAS  Google Scholar 

  19. Henderson D, Habernicht V-F, Nishino Y, et al (1986): Aromatase inhibitors and benign prostatic hyperplasia. J Steroid Biochem 25:867–876.

    Article  PubMed  CAS  Google Scholar 

  20. Ekman P, Barrack ER, Greene GL, et al (1983): Estrogen receptors in human prostate evidence for multiple binding sites. J Clin Endocrinol Metab 57:166–176.

    Article  PubMed  CAS  Google Scholar 

  21. Schwarzel WC, Kruggel W, Brodie HJ (1973): Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92:866–880.

    Article  PubMed  CAS  Google Scholar 

  22. Thompson EA, Siiteri PK (1974): The involvement of human placental microsome cytochrome P450 in aromatization. J Biol Chem 249:5373–5378.

    PubMed  CAS  Google Scholar 

  23. Chakraborty J, Hopkins R, Parke DV (1972): Inhibition studies in the aromatization of androstenedione by human placental microsomal preparations. Biochem J 130:190.

    Google Scholar 

  24. Uzgris VI, Whipple CA, Salhanick HA (1977): Stereoselective inhibition of cholesterol side-chain cleavage by enantiomers of aminoglutethimide. Endocrinology 101:89.

    Article  Google Scholar 

  25. Whipple CA, Colton T, Strauss JM, et al (1978): Comparison of luteolytic potencies of aminoglutethimide in the rabbit and rat. Endocrinology 103:1605.

    Article  PubMed  CAS  Google Scholar 

  26. Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ (1977): The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reporduc-tion and breast cancer. Endocrinology 100:1684–1695.

    Article  PubMed  CAS  Google Scholar 

  27. Brodie AMH, Schwarzel WC, Brodie HJ (1976): Studies on the mechanism of estrogen biosynthesis in the rat ovary. J Steroid Biochem 7:787–793.

    Article  PubMed  CAS  Google Scholar 

  28. Santen RJ, Worgul TJ, Samojlik E, et al (1981): Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast carcinoma. N Engl J Med 305:545–551.

    Article  PubMed  CAS  Google Scholar 

  29. Brodie AMH, Santen RJ (1986): Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. CRC Crit Rev Oncol/Hematol 5:361–396.

    Article  CAS  Google Scholar 

  30. Coombes RC, Goss P, Dowsett M, et al (1984): 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 2:1237–1239.

    Article  PubMed  CAS  Google Scholar 

  31. Brodie AMH, Marsh DA, Brodie HJ (1979): Aromatase inhibitors, IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxyandrostene-3,17-dione. J Steroid Biochem 10:423.

    Article  PubMed  CAS  Google Scholar 

  32. Brodie AMH, Brodie HJ, Garrett WM, et al (1982): The effect of aromatase inhibitor 1,4,6-androstatrienendione (ATD) on DMBA-induced mammary tumors in the rat and its mechanism of action in vivo. Biochem Pharmacol 31:2017.

    Article  PubMed  CAS  Google Scholar 

  33. Koos RD, Lemaire WJ, Hung TT, Brodie AMH (1985): Comparison of the effects of 4-OHA on aromatase activity in granulosa cells from preovulatory follies of rats, rabbits and humans steroids. Steroids 45:143–150.

    Article  PubMed  CAS  Google Scholar 

  34. Brodie AMH, Garrett WM, Hendrickson JR, et al (1981): Inactivation of aromatase in vivo. Steroids 38:693–701.

    Article  PubMed  CAS  Google Scholar 

  35. Covey DF, Hood WF (1981) Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-acetoxy- and 4-hydroxyandrostenedione. Mol Pharmacol 21:173–180.

    Google Scholar 

  36. Covey DF, Hood WF (1981): Enzyme generated intermediates derived from 4-androstene-3,6,17-dione and l,4,6-androstatiene-3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108:1594–1599.

    Article  Google Scholar 

  37. Covey DF, Hood WF, Parikh VD (1981): 10ß-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of estrogen biosynthesis. J Biol Chem 256:1076.

    PubMed  CAS  Google Scholar 

  38. Metcalf BW, Wright CL, Burkhart JP, Johnston JO (1981): Substrate-induced inactivation of aromatase by allenic and acetylenic steroids. J Am Chem Soc 103:3221–3222.

    Article  CAS  Google Scholar 

  39. Johnston JO, Metcalf BW (1984): Aromatase: a target enzyme in breast cancer. In Sunkara P (ed): Novel Approaches of Cancer Chemotherapy. New York, Academic Press, pp 307–328.

    Google Scholar 

  40. Walsh C (1982): Suicide substrates: mechanism-based enzyme inactivators. Tetrahedron 38:871–909.

    Article  CAS  Google Scholar 

  41. Sjoerdsma A (1981): Suicide inhibitors as potential drugs. Clin Pharmacol Exp Ther 30: 3–22..

    Article  CAS  Google Scholar 

  42. Brueggermeier RW, Floyd EE, Counsell RE (1978): Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis. J Med Chem 21:1007–1011.

    Article  Google Scholar 

  43. Mason JI, Murry BA, Olcott M, Sheets JJ (1985): Imidazole antimycotics: inhibitors of steroid aromatase. Biochem Pharmacol 34:1087–1092.

    Article  PubMed  CAS  Google Scholar 

  44. Steele RE, Mellor L, Sawyer WK, et al (1986): In vitro and in vivo inhibition of estrogen biosynthesis by a potent selective nonsteroidal aromatase inhibitor. Paper presented at the meeting of the 68th Annual Endocrine Society, Anaheim, CA, Abst #337.

    Google Scholar 

  45. Marsh DA, Brodie HJ, Garrett W, et al (1985): Aromatase inhibitors: synthesis and biological activity of androstenedione derivatives. J Med Chem 28:788–795.

    Article  PubMed  CAS  Google Scholar 

  46. Brodie AMH, Garrett WM, Hendrickson JR, Tsai-Morris CH (1982): Effects of 4-hydroxyandrostenedione and other compounds in the DMBA breast carcinoma model. Cancer Res (Suppl) 42:3360s-3364s.

    PubMed  CAS  Google Scholar 

  47. Johnston JO, Wright CL, Metcalf BW (1984): Biochemical and endocrine properties of a mechanism based inhibitor of aromatase. Endocrinology 115:776–785.

    Article  PubMed  CAS  Google Scholar 

  48. Huggins C, Briziarelli G, Sutton H (1959): Rapid induction of mammary carcinoma in the rat and the influence of hormones on tumors. J Exp Med 109:25–42.

    Article  PubMed  CAS  Google Scholar 

  49. Guillino PM, Pettigrew HM, Grantham FH (1975): Nitrosomethylurea as mammary gland carcinogen in rats. J Nat Cancer Inst 54:401–409.

    Google Scholar 

  50. Jordan VC (1976): Effects of tamoxifen on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 12:419–424.

    Article  PubMed  CAS  Google Scholar 

  51. DeSombre ER, Arbogast LY (1974): Effect of the antiestrogen C1628 on the growth of rat mammary tumors. Cancer Res 34:1971–1976.

    PubMed  CAS  Google Scholar 

  52. Puett D, Brandt ME, Covey DF, Zimniski SJ (1986): Characterization of a potent inhibitor of aromatase: inhibition of the rat ovarian enzyme and regression of estrogen dependent mammary tumors by 10-propargylestr-4-ene-3,17-dione. Proceedings of the 1st International Congress on Cancer and Hormones, Rome, Italy.

    Google Scholar 

  53. Wing LC, Garrett WM, Brodie AMH (1985): The effects of aromatase inhibitors, aminoglutethimide and 4-hydroxyandrostenedione and other compounds in the DMBA breast carcinoma model. Cancer Res 45:2425–2428.

    PubMed  CAS  Google Scholar 

  54. Wing LC, Hammond JO, Brodie AMH (1988): Differential responses of sex steroid target tissues of rats treated with aromatase inhibitor 4-hydroxyandrostenedione. Endocrinology. in press.

    Google Scholar 

  55. Santen RJ, Samojlik E, Wells SA (1980): Resistance of the ovary to blockade of aromatiza-tion with aminoglutethimide. J Clin Endocrinol Metab 51:473–477.

    Article  PubMed  CAS  Google Scholar 

  56. Brodie AMH, Longcope C (1980): Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy androstenedione. Endocrinology 106:19–21.

    Article  PubMed  CAS  Google Scholar 

  57. Johnston JO, Wright CL, Femino AM, Longcope C (1986): Inhibition of peripheral aromatization in baboons by a ‘suicide’ aromatase inhibitor (MDL 18,962). Paper presented at the 68th Annual Meeting of the Endocrine Society, Anaheim, CA, Abst #69.

    Google Scholar 

  58. Bonnetere J, Cappelacre R, Mauriac A, et al (1984): Low-dose aminoglutethimide in advanced breast cancer—preliminary report of a multicenter comparative trial: In Nagel GA, Santen RJ: Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer. Hans Huber Publishers, Berne, Stuttgart, Vienna, pp 104–108.

    Google Scholar 

  59. Cunningham D, Powles TJ, Dowsett M, et al (1987): Oral 4-hydroxyandrostenedione is a new, active endocrine treatment for breast cancer. Cancer Chemother Pharmacol 20:253–255.

    Article  PubMed  CAS  Google Scholar 

  60. Hayward JL, Carbone PP, Heuson J-C, et al (1977): Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1294.

    Article  PubMed  CAS  Google Scholar 

  61. Coombes RC, Powles TJ, Gazet J-C, et al. (1980): Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet 1:296–298.

    Article  PubMed  CAS  Google Scholar 

  62. Dowsett M, Goss PE, Powles TJ, et al (19): Use of the aromatase inhibitor, 4-hydroxyandrostenedione in postmenopausal breast cancer: optimisation of therapeutic dose and route. Cancer Res 47:1957–1961, 1987.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Angela M. H. Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell Dowsett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Charles Coombes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

    C. Kent Osborne

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Brodie, A.M.H., Dowsett, M., Coombes, R.C. (1988). Aromatase Inhibitors as New Endocrine Therapy for Breast Cancer. In: Osborne, C.K. (eds) Endocrine Therapies in Breast and Prostate Cancer. Cancer Treatment and Research, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1731-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1731-9_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8974-6

  • Online ISBN: 978-1-4613-1731-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation